Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Fig. 1

Patient disposition (ITT population). aOne patient, identified as participating in another clinical study during this study, was removed from all efficacy analyses (n = 354) but retained in all safety analyses (n = 355). bOne patient receiving revefenacin 350 μg was withdrawn from the study by the investigator on D6 due to a non-treatment–emergent prolonged QTcF (>500 msc) during the screening electrocardiogram. The subject is included in both the ITT and safety populations though the prolonged QTcF adverse event is not contained in the treatment-emergent AE summaries. Abbreviations: AE: adverse event; ITT: intent to treat; QTcF: Fridericia formula for QT interval correction

Back to article page